Improving the continuity of care following discharge of patients hospitalized with heart failure: Is the discharge summary adequate?

Canadian Journal of Cardiology

Volumn 19, Issue 4, 2003, Pages 365-370

  Raval, Amish N ^a   Marchiori, Gordon E ^a   Arnold, J Malcolm O ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

ACE inhibitors; Congestive heart failure; Health care delivery; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; INSULIN; LISINOPRIL; LONG ACTING DRUG; LOOP DIURETIC AGENT; NITRATE; ORAL ANTIDIABETIC AGENT; WARFARIN;

ADULT; AGED; AORTA STENOSIS; ARTICLE; CARDIOMYOPATHY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG USE; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH SERVICE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPOTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; PATIENT CARE; PATIENT INFORMATION; PRESCRIPTION; PRIMARY MEDICAL CARE; RISK FACTOR; RISK MANAGEMENT; SIDE EFFECT; TEACHING HOSPITAL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT PLANNING;

ADULT; AFTERCARE; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CONTINUITY OF PATIENT CARE; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITALS, TEACHING; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; ONTARIO; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT DISCHARGE; QUALITY ASSURANCE, HEALTH CARE; RETROSPECTIVE STUDIES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0038290691     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Graves EJ. 1999 Summary: National Hospital Discharge Survey. Advance Data from Vital Health Statistics, No 199. Hyattsville: National Centre for Health Statistics, 1989.
2. Ghali JK, Cooper R, Ford E. Trends in hospitalization rates for hearts failure in the United States, 1973-1986. Arch Intern Med 1990;150:769-73.
3. Kannel WB, Pinsky J. Trends in cardiac failure incidence and causes over three decades in the Framing study. J Am Coll Cardiol 1991;17:87A.
4. Ho K, Anderson K, Kannel W, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88:107-15.
5. Sutton G. Epidemiologic aspects of heart failure. Am Heart J 1990;120:1538-40.
6. McMurray J, McDonagh T, Morrison CE, et al. Trends in hospitalization for heart failure in Scotland 1980-1990. Eur Heart J 1993;14:1158-62.
7. Cowie MR, Mosterd A, Wood DA, et al. The epidemiology of heart failure. Eur Heart J 1997;18:208-25.
8. Krumhoz H, Parent E, Tu N, et al. Readmission after hospitalization for congestive heart failure among Medicare benificiaries. Arch Intern Med 1997;157:99-104.
9. McAlister FA, Teo KK, Taher M, et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J 1999;138:87-94.
10. Chin M, Goldman L. Correlates of early hospital readmission or death in patients with congestive heart failure. Am J Cardiol 1997;79:1640-4.
11. Johnstone D, Abdulla A, Arnold JMO, et al. Diagnosis and management of heart failure. Canadian Cardiovascular Society's Consensus Conference. Can J Cardiol 1994;10:613-31.
12. Konstam MA, Dracup K, Baker DW, et al. Heart Failure: Evaluation and Care of Patients with Left Ventricular Systolic Dysfunction. Rockville: US Dept of Health and Human Services, Agency for Health Care Policy and Research, 1994.
13. ACC/AHA Task Force. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Failure Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol 1995;26:1376-98.
14. The Task Force on Heart Failure of the European Society of Cardiology. The guidelines for the diagnosis of heart failure. Br Heart J 1995;16:741-51.
15. CONSENSUS Trial Study Group. The effects of enapril on mortality in severe congestive heart failure - Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
16. SOLVD Investigators. The effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-92.
17. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure (V-HeFT II). N Engl J Med 1991;325;303-10.
18. Pfeffer M, Braunwald E, Moye S, et al. Effect of captopril on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement (SAVE) Trial. N Engl J Med 1992;327:669-77.
19. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
20. Metroprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-6.
21. U. S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
22. Merit HF group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized interventions trial in congestive heart failure. Lancet 1999;353:2001-7.
23. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Study II: A randomized trial. Lancet 1999;353:9-13.
24. Cohn J, Archibald D, Phil M. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study (V-HeFT I). N Engl J Med 1986;314:1547-52.
25. ELITE Study Investigators. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.
26. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: (Randomized trial-the Losartan Heart Failure Survival Study, ELITE II). Lancet 2000;355:1582-7.
27. The Digtalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-34.
28. Packer M, Gheorghiade M, Young J, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. Randomized Assessment of the effect of Digoxin on inhibitors of the Angiotensin-Converting Enzyme Study (RADIANCE). N Engl J Med 1993;329:1-51.
29. Jaeschke R, Oxman A, Guyatt G. To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systematic overview and meta-analysis. Am J Med 1990;88:279-86.
30. Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
31. The Large State Peer Review Organization Consortium. Heart failure treatment with angiotensin-converting enzyme inhibitors in hospitalized Medicare patients in 10 large states. Arch Intern Med 1997;157:1103-7.
32. McDermott M, Feinglass J, Sy J, Gheorghiade M. Hospitalized congestive heart failure patients with preserved versus abnormal left ventricular systolic function: Clinical characteristics and drug therapy. Am J Med 1995;99:629-35.
33. McDermott M, Feinglass J, Lee P, et al. Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure. Am Heart J 1997;134:728-36.
34. Krumholz HM, Vaccarino V. Determinants of appropriate use of angiotensin-converting enzyme inhibitors after acute myocardial infarction in person ≥65 years of age. Am J Cardiol 1997;79:581-6.
35. Havranek E, Abrams F, Stevens E, et al. Determinants of mortality in elderly patients with heart failure. The role of angiotensin-converting enzyme inhibitors. Arch Intern Med 1998;158:2024-8.
36. Philbin E, Andreaou C, Rocco T, et al. Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol 1996;77:832-8.
37. Pearson T, Theodore P. The treatment gap in coronary artery disease and heart failure: Community standards and the post-discharge patient. Am J Cardiol 1997;80:45H-52H.
38. Barron H, Michaels A, Maynard C, et al. Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: Data from the National Registry of Myocardial Infarction 2. J Am Coll Cardiol 1998;32:360-7.
39. Hillis GS, Al-Mohammad A, Wood M, et al. Changing patterns of investigation and treatment of cardiac failure in hospital. Heart 1996;76:427-9.
40. Krumholz H, Wang Y, Parent E, et al. Quality of care for elderly patients hospitalized with heart failure. Arch Intern Med 1997;157:2242-7.
41. Choy A, Darbar D, Lang C, et al. Detection of left ventricular dysfunction after acute myocardial infarction: Comparison of clinical, echocardiographic and neurohormonal methods. Br Heart J 1994;72:16-22.
42. Clarke K, Gray D, Hampton JR. Evidence of inadequate investigation and treatment of patients with heart failure. Br Heart J 1994;71:584-7.
43. Edep ME, Shah NB, Tateo IM, et al. Differences between primary care physicians and cardiologists in management and congestive heart failure: Relation to practice guidelines. J Am Coll Cardiol 1997;30:518-26.
44. Brown AD, Garber AM. Cost effectiveness of coronary heart disease prevention strategies in adults. Pharmacoeconomics 1998;14:27-48.
45. Gonzalez ER. The pharmacoeconomic benefits of cholesterol reduction. Am J Manag Care 1998;4:223-30.
46. Baxter T, Milner P, Wilson K, et al. A cost-effective, community based heart health promotion project in England: Prospective comparative study. BMJ 1997;315:582-5.
47. Stone NJ. The clinical and economic significance of atherosclerosis. Am J Med 1996;101:4A6S-9S.
48. Wright J, Strang JR. Reducing the risk after coronary artery bypass surgery: Documentation of risk factors and communication between hospital and general practice. Public Health 1997;111:157-60.
49. Luzier A, Forrest A, Adelman M, et al. Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. Am J Cardiol 1998;82:465-9.
50. McDermott MM, Lee P, Mehta S, et al. Patterns of angiotensin-converting enzyme inhibitor prescriptions, education interventions and outcomes among hospitalized patients with heart failure. Clin Cardiol 1998;21:261-8.
51. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS study group. Circulation 1999;100:2312-8.
52. Rauh RA, Schwabauer NJ, Enger E, et al. A community hospital-based congestive heart failure program: Impact on length of stay, admission and readmission rates, and cost. Am J Manag Care 1999;5:37-43.
53. Cardozo L, Ahrens S, Steinberg J, et al. Implementing a clinical pathway for congestive heart failure: Experiences at a teaching hospital. Qual Manag Health Care 1998;1:1-12.
54. Paul S. Implementing an outpatient heart failure clinic: The nurse practitioner role. Heart Lung 1997;26:486-91.
55. Rich MW, Vinson JM, Sperry J, et al. Prevention of readmission in elderly patients with congestive heart failure: Results of a prospective, randomized pilot study. J Gen Intern Med 1993;11:585-90.
56. Smith LE, Fabbri AS, Pai R, et al. Symptomatic improvement and reduced hospitalization for patients attending a cardiomyopathy clinic. Clin Cardiol 1997;11:949-54.
57. West JA, Miller NH, Parker KM, et al. A comprehensive management system for heart failure improves clinical outcomes and reduces medical resource utilization. Am J Cardiol 1997;79:58-63.
58. Hanumanthu S, Butler J, Chomsky D, et al. Effect of a heart failure program on hospitalization frequency and exercise tolerance. Circulation 1997;96:2842-8.
59. Cline CM, Israelsson BY, Willenheimer RB, et al. Cost effective management program for heart failure reduces hospitalization. Heart 1998;80:442-6.
60. Rich M, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190-5.
61. Arnold JMO, Nadeau L, Calhoun M, Marchiori G. Reduction of readmission for heart failure following in-hospital patient education. Can J Cardiol 1997;13(Suppl C):104C.
62. West J, Miller N, Parker K, et al. A comprehensive management system for heart failure improves clinical outcomes and reduces medical resource utilization. Am J Cardiol 1997;79:58-63.
63. Parmley, WW. Cost effective management of heart failure. Clin Cardiol 1996;19:240-5.
64. Block L, Fredericks LA. The design and implementation of a disease management program for congestive heart failure at a community hospital. Congest Heart Fail 1997;22-37.